You have 9 free searches left this month | for more free features.

Pi3K

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Endometrial Cancer, Ovarian Cancer Trial in Houston (Copanlisib, fulvestrant)

Recruiting
  • Endometrial Cancer
  • Ovarian Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2022

Relapsed/Refractory Large Granular T Lymphocytic Leukemia Trial in Zhoukou, Tianjin (Linperlisib)

Not yet recruiting
  • Relapsed/Refractory Large Granular T Lymphocytic Leukemia
  • Zhoukou, Henan, China
  • +1 more
Dec 22, 2022

Autoimmune Hemolytic Anemia, Failure of Two Rounds of Treatment Trial in Zhoukou, Tianjin (Linperlisib)

Not yet recruiting
  • Autoimmune Hemolytic Anemia
  • Failure of Two Rounds of Treatment
  • Zhoukou, Henan, China
  • +1 more
Jan 7, 2023

Hyperglycemia Drug Induced Trial in Durham (REMD-477)

Terminated
  • Hyperglycemia Drug Induced
  • REMD-477
  • Durham, North Carolina
    Duke University Medical Center
Nov 4, 2022

Bile Acids in Acute Insulin Resistance

Recruiting
  • PI3K Gene Mutation
  • +4 more
  • Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
  • New York, New York
    Columbia University Medical Center
Oct 6, 2022

Metastatic Breast Cancer Trial in East Melbourne (BYl719)

Completed
  • Metastatic Breast Cancer
  • East Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Aug 11, 2022

Estrogen Receptor-positive Breast Cancer Trial in Nashville (2-Week Ketogenic Diet, Letrozole)

Recruiting
  • Estrogen Receptor-positive Breast Cancer
  • Nashville, Tennessee
    Vanderbilt-Ingram Cancer Center
Sep 20, 2022

Leukemia, Acute Lymphocytic Trial in Durham (Copanlisib)

Recruiting
  • Leukemia, Acute Lymphocytic
  • Durham, North Carolina
    Duke Cancer Center
Jun 28, 2022

Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer Trial in Miami (AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor +

Not yet recruiting
  • Breast Cancer
  • +3 more
  • Miami, Florida
    University of Miami
Apr 12, 2023

Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer Trial in Boston (Palbociclib, Gedatolisib)

Recruiting
  • Lung Cancer Squamous Cell
  • +3 more
  • Boston, Massachusetts
  • +2 more
Jan 9, 2023

Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer Trial (OP-1250, Ribociclib, Alpelisib)

Not yet recruiting
  • Metastatic Breast Cancer
  • +3 more
  • (no location specified)
Aug 18, 2022

Melanoma and Other Malignant Tumors of Skin, Metastatic Melanoma Trial in Houston (GSK2636771, Pembrolizumab)

Active, not recruiting
  • Melanoma and Other Malignant Neoplasms of Skin
  • Metastatic Melanoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 22, 2022

HER2-positive Breast Cancer Trial (Inavolisib, PHESGO, Endocrine therapy)

Not yet recruiting
  • HER2-positive Breast Cancer
  • (no location specified)
Mar 23, 2022

Advanced Solid Tumor Trial in Sutton, Manchester (SL-901)

Recruiting
  • Advanced Solid Tumor
  • Sutton, Surrey, United Kingdom
  • +1 more
May 16, 2022

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,

Active, not recruiting
  • Estrogen Receptor-positive Breast Cancer
  • +5 more
  • PI3K inhibitor BYL719
  • +3 more
  • Boston, Massachusetts
  • +1 more
Oct 14, 2022

Everolimus-containing Chemotherapy in HER2- mBC PI3K/AKT/mTOR

Completed
  • Breast Cancer
  • +2 more
  • No intervention, it was a retrospective study.
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Sep 13, 2021

PIK3CA Mutation-Related Tumors Trial in Shanghai (WX390)

Completed
  • PIK3CA Mutation-Related Tumors
  • Shanghai, Shanghai, China
    Shanghai East Hospital
Nov 9, 2023

Locally Advanced Breast Cancer, Metastatic Breast Cancer Trial in Batumi, Tbilisi (Tenalisib)

Active, not recruiting
  • Locally Advanced Breast Cancer
  • Metastatic Breast Cancer
  • Batumi, Georgia
  • +2 more
May 2, 2022

Locally Advanced Malignant Solid Tumor, Metastatic Malignant Tumor in the Bone, Metastatic Malignant Solid Tumor Trial

Withdrawn
  • Locally Advanced Malignant Solid Neoplasm
  • +3 more
  • (no location specified)
May 24, 2022

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (TGR-1202, Ibrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Mantle Cell Lymphoma
  • Monterey, California
  • +4 more
Aug 29, 2022

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Atlanta, Columbus (drug, biological,

Completed
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +8 more
  • PI3K inhibitor BKM120
  • +3 more
  • Atlanta, Georgia
  • +1 more
Jun 27, 2022

Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation Trial in Shanghai (Everolimus, Investigator's Choice of

Not yet recruiting
  • Triple Negative Breast Cancer
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 25, 2023

Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 23, 2022

Breast Cancer, PI3K, Alpelisib Trial in France (Alpelisib, Chemotherapy)

Active, not recruiting
  • Breast Cancer, PI3K, Alpelisib
  • Angers, France
  • +13 more
Mar 8, 2022

Colorectal Cancer, Gastric Cancer, HER2-negative Breast Cancer Trial (TOS-358)

Not yet recruiting
  • Colorectal Cancer
  • +8 more
  • (no location specified)
Jan 5, 2023